Yonsei Criteria, a Potential Linkage to Intratumoral Foxp3+/CD8+ Ratio for the Prediction of Oncologic Outcomes in Resected Left-Sided Pancreatic Cancer

키워드

참고문헌 (32)

1. Hidalgo M, "Pancreatic cancer", N Engl J Med, 362, pp.1605~1617 (2010)
2. 정윤숙, "Physical Inactivity and Unhealthy Metabolic Status Are Associated with Decreased Natural Killer Cell Activity", Yonsei Medical Journal, 59(4), pp.554~562 (2018), 연세대학교의과대학[DOI]
3. Bates GJ, "Quantification of regulatory T cells enables the identification of highrisk breast cancer patients and those at risk of late relapse", J Clin Oncol, 24, pp.5373~5380 (2006)
4. Fu J, "Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients", Gastroenterology, 132, pp.2328~2339 (2007)
5. Kim HI, "The ratio of intra-tumoral regulatory T cells(Foxp3+)", helper T cells(CD4+)is a prognostic factor and associated with recurrence pattern in gastric cardia cancer, 2011, pp.104, 728~733
6. Zhang L, "Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer", N Engl J Med, 348, pp.203~213 (2003)
7. Balch CM, "Patterns of human tumor-infiltrating lymphocytes in 120 human cancers", Arch Surg, 125, pp.200~205 (1990)
8. Clemente CG, "Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma", Cancer, 77, pp.1303~1310 (1996)
9. Gao Q, "Intratumoral balance of regulatory and cytotoxic T cells is associated with prog-nosis of hepatocellular carcinoma after resection", J Clin Oncol, 25, pp.2586~2593 (2007)
10. Petersen RP, "Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients", Cancer, 107, pp.2866~2872 (2006)
11. Cho Y, "CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma", Cancer Res, 63, pp.1555~1559 (2003)
12. Duffour MT, "A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes", Eur J Immunol, 29, pp.3329~3337 (1999)
13. Bleackley RC, "A molecular view of cytotoxic T lymphocyte induced killing", Biochem Cell Biol, 83, pp.747~751 (2005)
14. Sakaguchi S, "Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses", Annu Rev Immunol, 22, pp.531~562 (2004)
15. Hori S, "Control of regulatory T cell development by the transcription factor Foxp3", Science, 299, pp.1057~1061 (2003)
16. Hwang HK, "Prognostic impact of the tumor-infiltrating regulatory T-cell(Foxp3+)", activated cytotoxic T lymphocyte(granzyme B+)ratio on resected left-sided pancreatic cancer, 2016, pp.12, 4477~4484
17. Choi SH, "Multimedia article. Laparoscopic modified anterior RAMPS in well-selected left-sided pancreatic cancer : technical feasibility and interim results", Surg Endosc, 25, pp.2360~2361 (2011)
18. Choi SH, "Robotic anterior RAMPS in well-selected left-sided pancreatic cancer", J Gastrointest Surg, 16, pp.868~869 (2012)
19. Lee SH, "Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria : long-term(>median 3 years)oncologic outcomes", Surg Endosc, 28, pp.2848~2855 (2014)
20. Fukunaga A, "CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma", Pancreas, 28, pp.e26~e31 (2004)
21. Ikemoto T, "Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients", Pancreas, 33, pp.386~390 (2006)
22. Wachsmann MB, "Pancreatic ductal adenocarcinoma : a review of immunologic aspects", J Investig Med, 60, pp.643~663 (2012)
23. Hiraoka N, "Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions", Clin Cancer Res, 12, pp.5423~5434 (2006)
24. Slidell MB, "Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma : a large, population-based analysis", Ann Surg Oncol, 15, pp.165~174 (2008)
25. Hwang HK, "Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer : the need for strict transfusion policy", J Hepatobiliary Pancreat Sci, 23, pp.497~507 (2016)
26. Burrows L, "Effect of blood transfusions on colonic malignancy recurrent rate", Lancet, 2, pp.662~ (1982)
27. Katz SC, "Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma", Ann Surg, 249, pp.617~623 (2009)
28. Nagai S, "Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas", Pancreas, 40, pp.3~9 (2011)
29. Blajchman MA, "Allogeneic blood transfusion-induced enhancement of tumor growth : two animal models showing amelioration by leukodepletion and passive transfer using spleen cells", Blood, 81, pp.1880~1882 (1993)
30. Tempero MA, "Pancreatic adenocarcinoma, version 2. 2014 : featured updates to the NCCN guidelines", J Natl Compr Canc Netw, 12, pp.1083~1093 (2014)
31. Yoshida S, "Clinical significance of tumor-infiltrating T cells and programed death ligand-1 in patients with pancreatic cancer", Cancer Invest, 37, pp.463~477 (2019)
32. Sideras K, "Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer", Int J Cancer, 141, pp.572~582 (2017)

관련 논문AI추천